Amgen Scoops Up Onyx For $10.4 Bln - Presented by: The Aol. On Network

How do you re-build your pipeline in the biotech world? You buy it. Amgen is plopping down $10.4 billion for Onyx Pharmaceuticals after trying to seal the deal for two-months. That all cash price tag makes this the fifth largest biotech deal on record. CEO Bob Bradway has been gobbling up companies and their products, with two of Amgen's revenue drivers now facing safety concerns and four of its five top-selling treatments facing patent expirations beginning in 2015.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
BAC $ 17.98 0.05 ▲ 0.28%
GILD $ 91.29 1.84 ▲ 2.06%
RAD $ 7.26 0.09 ▼ 1.22%
ARCP $ 8.33 unch
S $ 4.19 0.05 ▼ 1.18%
GE $ 25.83 0.05 ▼ 0.19%
PBR $ 7.60 0.11 ▼ 1.43%
AAPL $ 112.01 0.53 ▼ 0.47%

As of 12/24/2014, 02:12 PM
More Most Active